Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 5Gynecologic 1

Conditions

Ovarian Neoplasms 5Endometrial Neoplasms 5Uterine Cervical Neoplasms 2Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Site 1Low Grade Serous Ovarian Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Granulosa Cell Ovarian Cancer 1Fallopian Tube Neoplasms 1Endometrial Stromal Tumors 1Carcinoma 1Breast Diseases 1

Interventions

pembrolizumab 42Nivolumab 13Carboplatin 11Cyclophosphamide 10olaparib 7Paclitaxel 7Ipilimumab 7fludarabine 6Gemcitabine 6durvalumab 5lenvatinib 4cemiplimab 4atezolizumab 4Specimen Handling 4Oxaliplatin 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fulvestrant 4Fluorouracil 4Cisplatin 4Bevacizumab 4veliparib 3spartalizumab 3sacituzumab govitecan 3liposomal doxorubicin 3avelumab 3aldesleukin 3Taxes 3Interleukin-2 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Anastrozole × Gynecologic × Clear all
NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Terminated
41 enrolled
BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡